{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:39:34Z","timestamp":1787614774902,"version":"build-2736575974"},"reference-count":176,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["NET-2018\\u201312365935"],"award-info":[{"award-number":["NET-2018\\u201312365935"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21267"],"award-info":[{"award-number":["21267"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1053\/j.seminhematol.2025.06.005","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:41:00Z","timestamp":1751370060000},"page":"155-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories"],"prefix":"10.1053","volume":"62","author":[{"given":"Luca","family":"Guarnera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Silvestrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Attardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2025.06.005_bib0001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0002","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0003","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood-2023-185709","article-title":"Unraveling the impact of 2022 classifications on secondary acute myeloid leukemia: assessing the true qualification power of diagnostic qualifiers","volume":"142","author":"Attardi","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0004","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0005","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0006","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0007","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","article-title":"Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting","volume":"7","author":"Attardi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0008","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1097\/HS9.0000000000000321","article-title":"Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management and follow-up","volume":"3","author":"Baliakas","year":"2019","journal-title":"Hemasphere"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0009","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1002\/hem3.112","article-title":"Prospective genetic germline evaluation in a consecutive group of adult patients aged\u2009<60 years with myelodysplastic syndromes","volume":"8","author":"Attardi","year":"2024","journal-title":"Hemasphere"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0010","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0011","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/hematology.2020006910","article-title":"Identifying potential germline variants from sequencing hematopoietic malignancies","volume":"2020","author":"Kraft","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101279","article-title":"Somatic mosaicism in inherited bone marrow failure syndromes","volume":"34","author":"Gutierrez-Rodrigues","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0014","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.seminhematol.2024.01.005","article-title":"Clonal hematopoiesis in children with predisposing conditions","volume":"61","author":"Attardi","year":"2024","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0015","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood-2013-11-538025","article-title":"Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis","volume":"123","author":"Skokowa","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0016","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41467-021-21588-4","article-title":"Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome","volume":"12","author":"Kennedy","year":"2021","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0017","first-page":"2853","article-title":"The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia","volume":"141","author":"Hakkarainen","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0018","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.stem.2023.01.006","article-title":"Clonal hematopoiesis driven by chromosome 1q\/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia","volume":"30","author":"Sebert","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0019","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bjh.17006","article-title":"Prevalence of germline GATA2 and SAMD9\/9L variants in paediatric haematological disorders with monosomy 7","volume":"191","author":"Yoshida","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0020","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood.2022017717","article-title":"Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management","volume":"145","author":"Sahoo","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0021","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germ line DDX41 mutations define a unique subtype of myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0022","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0023","first-page":"59","article-title":"P.aroxysmal nocturnal hemoglobinuria: biology and treatment","author":"Bravo-Perez","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0092-8674(00)81850-4","article-title":"Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise?","volume":"88","author":"Luzzatto","year":"1997","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood.2019000940","article-title":"Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0026","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/leu.2013.30","article-title":"Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia","volume":"27","author":"Lane","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0027","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.3324\/haematol.2013.101642","article-title":"Genetic characterization of acquired aplastic anemia by targeted sequencing","volume":"99","author":"Heuser","year":"2014","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0028","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood-2014-05-574889","article-title":"Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome","volume":"124","author":"Kulasekararaj","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0029","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cancergen.2015.01.007","article-title":"Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia","volume":"208","author":"Babushok","year":"2015","journal-title":"Cancer Genet"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0031","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.22.00710","article-title":"Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria","volume":"41","author":"Gurnari","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0032","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/blood.2020010586","article-title":"HLA class I allele-lacking leukocytes predict rare clonal evolution to MDS\/AML in patients with acquired aplastic anemia","volume":"137","author":"Hosokawa","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0033","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood.2021012895","article-title":"HLA associations, somatic loss of HLA expression, and clinical outcomes in immune aplastic anemia","volume":"138","author":"Zaimoku","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0034","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41375-022-01636-8","article-title":"Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia","volume":"36","author":"Groarke","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41375-022-01723-w","article-title":"Molecular landscape of immune pressure and escape in aplastic anemia","volume":"37","author":"Pagliuca","year":"2023","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0036","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-102-2-169","article-title":"Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia","volume":"102","author":"Loughran","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0037","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41375-021-01231-3","article-title":"Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia","volume":"35","author":"Lundgren","year":"2021","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0038","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s12185-022-03310-2","article-title":"T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia","volume":"115","author":"Kawakami","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0039","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood-2023-182344","article-title":"Unveiling the spectrum of inborn errors of immunity: lessons from T-cell LGL clonal expansions","volume":"142","author":"Bravo-Perez","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0040","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1182\/blood-2013-04-494930","article-title":"STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients","volume":"122","author":"Jerez","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0041","first-page":"1616","article-title":"Concurrence of myelodysplastic syndromes and large granular lymphocyte leukemia: clinicopathological features, mutational profile and gene ontology analysis in a single center","volume":"11","author":"Ai","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0042","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1038\/s41375-020-0928-4","article-title":"Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL)","volume":"34","author":"Komrokji","year":"2020","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0043","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41375-019-0601-y","article-title":"Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome","volume":"34","author":"Durrani","year":"2020","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0044","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41375-024-02460-y","article-title":"Clonal hematopoiesis in large granular lymphocytic leukemia","volume":"39","author":"Kawashima","year":"2025","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cbi.2009.11.025","article-title":"Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia","volume":"184","author":"Qian","year":"2010","journal-title":"Chem Biol Interact"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0046","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051054","article-title":"Therapy-related myeloid neoplasm: biology and mechanistic aspects of malignant progression","volume":"12","author":"Travaglini","year":"2024","journal-title":"Biomedicines"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0047","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2174\/1381612811319130016","article-title":"Recent developments of DNA poisons\u2013human DNA topoisomerase ii\u03b1 inhibitors\u2014as anticancer agents","volume":"19","author":"Pogorel\u010dnik","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0048","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1080\/14656566.2019.1621292","article-title":"Topoisomerase II inhibitors in AML: past, present, and future","volume":"20","author":"Economides","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0049","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2010.218","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy","volume":"24","author":"Carney","year":"2010","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/modpathol.2011.158","article-title":"Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"25","author":"Zhou","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0051","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1189\/jlb.0113006","article-title":"Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia","volume":"94","author":"Zhou","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2023.09.005","article-title":"Microenvironment in acute myeloid leukemia: focus on senescence mechanisms, therapeutic interactions, and future directions","volume":"129","author":"Guarnera","year":"2024","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0053","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/pros.23281","article-title":"Myelodysplastic syndromes and acute myeloid leukemia after radiotherapy for prostate cancer: a population-based study","volume":"77","author":"Wang","year":"2017","journal-title":"Prostate"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0054","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0055","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3109\/10428194.2014.970543","article-title":"Therapy-related myelodysplastic syndrome\/acute leukemia after multiple myeloma in the era of novel agents","volume":"56","author":"Gertz","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0056","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41409-024-02455-4","article-title":"Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma","volume":"60","author":"Elghawy","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0057","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/bjh.18766","article-title":"Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours","volume":"201","author":"Almanza-Huante","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0058","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/ijc.34162","article-title":"Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes","volume":"151","author":"Todisco","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0059","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-22-1622","article-title":"Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience","volume":"28","author":"Marmouset","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0060","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ijc.33269","article-title":"Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: a single-center experience","volume":"148","author":"Todisco","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0061","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/s41467-023-38515-4","article-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","volume":"14","author":"Kewan","year":"2023","journal-title":"Nat Commun"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.06.005_bib0062","first-page":"00129","article-title":"The potential promise of machine learning in myelodysplastic syndrome","volume":"S0037-1963","author":"Visconte","year":"2024","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0063","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0064","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"136","author":"Menssen","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0066","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0067","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0068","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1038\/s41375-022-01728-5","article-title":"SF3B1 mutated MDS: blast count, genetic co-abnormalities and their impact on classification and prognosis","volume":"36","author":"Huber","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0069","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0070","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2208176120","article-title":"Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells","volume":"120","author":"Fortin","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0071","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0072","doi-asserted-by":"crossref","first-page":"8589","DOI":"10.1073\/pnas.1407688111","article-title":"Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers","volume":"111","author":"Xu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0073","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0074","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15099","article-title":"Clonal evolution in myelodysplastic syndromes","volume":"8","author":"da Silva-Coelho","year":"2017","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0075","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0076","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0077","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0078","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0079","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0080","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0081","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/leu.2013.207","article-title":"Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0082","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0083","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0084","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0085","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0086","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10375","article-title":"Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan","volume":"74","author":"Nielsen","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0087","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/leu.2008.218","article-title":"Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)","volume":"22","author":"Reilly","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0088","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0089","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0090","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0091","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0092","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: mutation and karyotype-enhanced International prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0093","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0094","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Luque Paz","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0095","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","article-title":"RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features","volume":"4","author":"Coltro","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0096","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0097","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2009-06-226340","article-title":"Mutations of an E3 ubiquitin ligase c-cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia","volume":"115","author":"Muramatsu","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0098","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41375-024-02429-x","article-title":"Non canonical c-CBL mutations define a specific phenotype of myeloid neoplasia","volume":"39","author":"Guarnera","year":"2025","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0099","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","article-title":"MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen","volume":"3","author":"Ali","year":"2019","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0100","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.27136","article-title":"The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70\/plus\/plus v2.0) for primary myelofibrosis","volume":"99","author":"Loscocco","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0101","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0102","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0103","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0104","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0105","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0106","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0107","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.27271","article-title":"Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management","volume":"99","author":"Patnaik","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0108","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0109","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0111","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.leukres.2010.02.033","article-title":"Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations","volume":"34","author":"Szpurka","year":"2010","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0112","doi-asserted-by":"crossref","first-page":"E246","DOI":"10.1002\/ajh.26182","article-title":"Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)","volume":"96","author":"Montalban-Bravo","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0113","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0114","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027170","article-title":"BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia","author":"Tefferi","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0115","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjh.19060","article-title":"Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia","volume":"203","author":"Montalban-Bravo","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0116","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2501","article-title":"Atypical chronic myeloid leukaemia: a case of an orphan disease\u2014a multicenter report by the Polish Adult Leukemia Group","author":"Drozd-Soko\u0142owska","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0117","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-022-00622-8","article-title":"Myelodysplastic\/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T): mayo-Moffitt collaborative study of 158 patients","volume":"12","author":"Mangaonkar","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0118","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2014.8","article-title":"Myelodysplastic\/myeloproliferative neoplasms, unclassifiable (MDS\/MPN, U): natural history and clinical outcome by treatment strategy","volume":"28","author":"DiNardo","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0119","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients","volume":"34","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0121","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood.2021010764","article-title":"What\u2019s new in the pathogenesis and treatment of therapy-related myeloid neoplasms","volume":"138","author":"Voso","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0122","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1182\/blood-2002-04-1152","article-title":"The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia","volume":"100","author":"Seedhouse","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0123","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.3109\/10428194.2013.845885","article-title":"The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes","volume":"55","author":"Fabiani","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0124","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.3109\/10428194.2014.903475","article-title":"Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms","volume":"55","author":"Criscuolo","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.beha.2019.02.005","article-title":"Germline polymorphisms and the risk of therapy-related myeloid neoplasms","volume":"32","author":"Takahashi","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0126","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.29615","article-title":"Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia","volume":"122","author":"Churpek","year":"2016","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0127","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1038\/bcj.2015.44","article-title":"Fanconi anemia gene variants in therapy-related myeloid neoplasms","volume":"5","author":"Voso","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0128","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0129","doi-asserted-by":"crossref","first-page":"12031","DOI":"10.18632\/oncotarget.14509","article-title":"Clonal evolution in therapy-related neoplasms","volume":"8","author":"Fabiani","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0130","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/blood-2017-09-805879","article-title":"Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT","volume":"131","author":"Berger","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0131","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjh.18129","article-title":"Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy","volume":"198","author":"Voso","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0132","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1007\/s00277-024-05803-y","article-title":"The role of clonal progression leading to the development of therapy-related myeloid neoplasms","volume":"103","author":"Guarnera","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0133","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0134","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0135","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1200\/JCO.23.02547","article-title":"Clonal hematopoiesis and therapy-related myeloid neoplasms after autologous transplant for Hodgkin lymphoma","volume":"42","author":"Yan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0136","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010204","article-title":"The evolving protein engineering in the design of chimeric antigen receptor T cells","volume":"21","author":"Hughes-Parry","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0137","doi-asserted-by":"crossref","DOI":"10.3390\/cells12121586","article-title":"CAR T-cell therapy for cancer: latest updates and challenges, with a focus on B-lymphoid malignancies and selected solid tumours","volume":"12","author":"Tang","year":"2023","journal-title":"Cells"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0138","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0139","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0140","article-title":"Immunotherapy in acute myeloid leukemia: a literature review of emerging strategies","volume":"10","author":"Guarnera","year":"2023","journal-title":"Bioengineering (Basel)"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0141","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2024.029","article-title":"FLT3 Mutated acute myeloid leukemia after CD19 CAR-t cells","volume":"16","author":"Galli","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0142","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-022-00707-4","article-title":"Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma","volume":"12","author":"Alkhateeb","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0143","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0144","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0145","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/cncr.31914","article-title":"Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-hodgkin lymphoma","volume":"125","author":"Calip","year":"2019","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0146","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0147","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0140-6736(71)90998-6","article-title":"Leukaemic transformation of engrafted human marrow cells in vivo","volume":"1","author":"Fialkow","year":"1971","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0148","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/sj.bmt.1705332","article-title":"Development of donor cell derived acute myeloid leukemia after stem cell transplantation for chronic myeloid leukemia","volume":"37","author":"Pieroni","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0149","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/bmt.2008.224","article-title":"Myelofibrosis as the initial presentation of donor-derived myelodysplastic syndrome\/AML: failure of a lasting response to a second allogeneic transplant from the original donor","volume":"42","author":"Cutting","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0150","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ajh.20349","article-title":"Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma","volume":"79","author":"Matsunaga","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0151","first-page":"969","article-title":"Development of leukemia in donor cells after allogeneic stem cell transplantation\u2014a survey of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"90","author":"Hertenstein","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0152","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.26401","article-title":"Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation","volume":"97","author":"Kuno","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0153","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41375-018-0218-6","article-title":"European experience and risk factor analysis of donor cell-derived leukaemias\/MDS following haematopoietic cell transplantation","volume":"33","author":"Engel","year":"2019","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0154","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/leu.2016.63","article-title":"Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation","volume":"30","author":"Gondek","year":"2016","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0155","first-page":"1161","article-title":"Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals","volume":"135","author":"van Zeventer","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0156","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.seminhematol.2024.01.013","article-title":"TET2 mutation as prototypic clonal hematopoiesis lesion","volume":"61","author":"Guarnera","year":"2024","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0157","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2017.104","article-title":"Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient","volume":"31","author":"Herold","year":"2017","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0158","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2018.79.2184","article-title":"Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation","volume":"37","author":"Frick","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0159","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.21.02286","article-title":"Donor clonal hematopoiesis and recipient outcomes after transplantation","volume":"40","author":"Gibson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0160","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood-2018-07-861070","article-title":"Donor-derived MDS\/AML in families with germline GATA2 mutation","volume":"132","author":"Galera","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0161","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12185-020-02980-0","article-title":"Donor-derived myelodysplastic syndrome after allogeneic stem cell transplantation in a family with germline GATA2 mutation","volume":"113","author":"Sakata","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0162","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1111\/ajt.17174","article-title":"Donor-derived acute myeloid leukemia in solid organ transplantation","volume":"22","author":"Marchionni","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0163","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1182\/bloodadvances.2023011735","article-title":"Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN","volume":"8","author":"Davidson","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0164","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/bloodadvances.2018021469","article-title":"The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes","volume":"2","author":"McNamara","year":"2018","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0165","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1038\/s41375-024-02425-1","article-title":"Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase","volume":"38","author":"Walter","year":"2024","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0166","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0167","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.3324\/haematol.2019.219352","article-title":"Genomics of therapy-related myeloid neoplasms","volume":"105","author":"Kuzmanovic","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0168","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0169","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.clml.2021.09.019","article-title":"Secondary acute myeloid leukemia (sAML): similarly dismal outcomes of AML after an antecedent hematologic disorder and therapy related AML","volume":"22","author":"Lalayanni","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0170","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3897\/folmed.65.e98404","article-title":"Secondary acute myeloid leukemia and de novo acute myeloid leukemia with myelodysplasia-related changes\u2014close or complete strangers?","volume":"65","author":"Jagurinoski","year":"2023","journal-title":"Folia Med (Plovdiv)"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0171","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional Cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0172","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0173","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0174","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-022-01229-z","article-title":"Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure","volume":"15","author":"Short","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0175","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41409-020-01129-1","article-title":"ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation","volume":"56","author":"Jentzsch","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2025.06.005_bib0176","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106821","article-title":"Acute leukemia arising from myeloproliferative or myelodysplastic\/myeloproliferative neoplasms: a series of 372 patients from the PETHEMA AML registry","volume":"115","author":"Hern\u00e1ndez-Boluda","year":"2022","journal-title":"Leuk Res"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:49:42Z","timestamp":1768398582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":176,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0037196325000320"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.06.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}